

Abstract:

AGO-OVAR 12: A RANDOMIZED PLACEBO-CONTROLLED GCIG/ENGOT-INTERGROUP PHASE III TRIAL WITH CHEMOTHERAPY +/- NINTEDANIB FOR ADVANCED OVARIAN CANCER: OVERALL SURVIVAL RESULTS

Aims

AGO-OVAR12 study investigated the value of Nintedanib (N), an oral inhibitor of VEGFR, PDGFR, and FGFR in the treatment of newly diagnosed advanced ovarian cancer patients (pts). The data of final analysis of overall survival (OS) is reported here.

Method

Pts with FIGO IIB-IV ovarian cancer and upfront debulking surgery were randomly assigned (2:1) to receive six cycles of carboplatin (AUC5 or 6) and paclitaxel (175mg/m²) in addition to either 200 mg of Nintedanib (TC+N) or placebo (TC+PI) twice daily for up to 120 weeks. Primary endpoint was investigator assessed progression-free survival (PFS) and has been reported to be significantly better previously. Here we report final OS results.

Results

1,366 patients were recruited 12/2009 – 7/2011 by 9 study groups; 911 TC+N and 455 received TC+PI. Overall, 39% had a very high risk with FIGO III and residuals >1cm or FIGO IV while 61% had FIGO III and residuals ≤1cm or FIGO II (283 in TC+PI, 556 in TC+N). After 605 observed deaths, OS did not show statistically significant differences (median N+TC 62.0 vs PI+TC 62.8 months; HR 0.99; 95%CI:0.83 – 1.17; p=0.86). None of the subgroups defined by randomization strata, neither the high/low risk subgroups showed a statistically significant difference in OS between treatment groups. Adverse events leading to death occurred in 30 (3.3%) patients in TC+N and in 16 (3.6%) patients in TC+PI.

Conclusion

Although well tolerated in combination with TC, Nintedanib combination with TC did not affect OS compared to placebo. This is the first time these data are shown.

Co-authors

I. Ray-Coquard¹, D. Cibula², M.R. Mirza³, A. Reuss⁴, C. Ricci⁵, N. Colombo⁶, A. Zubernigg⁷, F. Goffin⁸, A. Gonzalez-Martin⁹, P.B. Ottevanger¹⁰, K. Baumann¹¹, L. Bjørge¹², A. Lesoin¹³, A. Burges¹⁴, P. Rosenberg¹⁵, M. Gropp-Meier¹⁶, M. Harrela¹⁷, P. Harter¹⁸, M. Merger¹⁹, A. du Bois¹⁸

¹GINECO & Centre Leon Berard & University Lyon, Medical Oncology, Lyon, France

²AGO & Charles University of Prague, Oncogynecologic Center- Dept. of Obstetrics and Gynecology, Prague, Czech Republic

³NSGO & Rigshospitalet Copenhagen University Hospital, Dept. of Oncology, Copenhagen, Denmark

⁴AGO & Philipps-University of Marburg, Coordinating Center for Clinical Trials, Marburg, Germany

⁵MITO & Università Cattolica del Sacro Cuore, Policlinico Gemelli, Rome, Italy

⁶MaNGO & European Institute of Oncology & University of Milan Bicocca, Gynecologic Oncology, Milano, Italy

⁷AGO-Austria & Bezirkskrankenhaus Kufstein, Dept. Gynecology and Obstetrics, Kufstein, Austria

⁸BGOG & University of Liège- CHU de Liège, Site Hôpital de la Citadelle, Liège, France

⁹GEICO & MD Anderson Cancer Center Madrid, Medical Oncology Department, Madrid, Spain

¹⁰DGOG & Radboud University Medical Centre, Department of Medical Oncology, Nijmegen, The Netherlands

¹¹AGO & Klinikum der Stadt Ludwigshafen gGmbH, Dept. of Gynecology, Ludwigshafen, Germany

¹²NSGO & Haukeland Universitetssykehus Bergen, Dept. Gynecology, Bergen, Norway

¹³GINECO & Centre Oscar Lambret, Gynecologic Cancer and medical oncology, Lille, France

¹⁴AGO & University of Muenich- Campus Grosshadern, Dept. Gynecology and Obstetrics, Muenich, Germany

¹⁵NSGO & University Hospital Linköping, Dept. of Oncology, Linköping, Sweden

¹⁶AGO & Oberschwabenklinik- Krankenhaus St. Elisabeth, Dept. Gynecology & Obstetrics, Ravensburg, Germany

¹⁷NSGO & Helsinki University Central Hospital, Dept. of Obstetrics and Gynecology, Helsinki, Finland

¹⁸AGO & Kliniken Essen Mitte- Evang. HuysSENS-Stiftung/Knappschaft GmbH, Dept. of Gynecology and Gynecologic Oncology, Essen, Germany

¹⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Medicine TA Oncology, Ingelheim, Germany